FIRST® – Omeprazole and FIRST® – Lansoprazole Unit-of-Use compounding kits make pharmacy compounding easier

Woburn, Mass., January 19, 2012 – CutisPharma, Inc. announced the introduction of FIRST® – Omeprazole and FIRST® – Lansoprazole Unit-of-Use oral suspension compounding kits. These new kits will help pharmacists dispense these compounded prescriptions containing widely used proton pump inhibitors (PPIs). Traditionally, compounded omeprazole and lansoprazole oral suspensions can take up to several hours to prepare and are quite unpleasant to the taste. With FIRST® – Omeprazole and FIRST® – Lansoprazole, pharmacists need only add the liquid suspension to the powder, shake, and then within minutes can dispense to the patient with improved flavoring.

“We invested a lot of time to develop these new suspension kits. The results are a pleasant tasting strawberry flavored medication with adequate stability once compounded.” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “These products offer another advantage for hospital use; since the suspensions are made using powders, and not pellets, our new compounded suspensions will flow more easily through nasogastric (NG) tubes, with minimal clogging compared to current practice. Also, our three different sizes of packaging, 3oz, 5oz, and 10oz, provide considerable prescribing flexibility.”

FIRST® products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST® – Omeprazole and FIRST® – Lansoprazole kits, the pharmacist can compound a prescription faster than those prepared in the conventional way. A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit- related adjustments.

CutisPharma now has twenty proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, six Magic Mouthwash kits, three omeprazole suspension kits, and three lansoprazole suspension kits. Several more compounding kits are in the planning stages. The use of FIRST® Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>.

The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through “compounding,” a means by which a pharmacist prepares a customized medication according to a doctor’s prescription to meet an individual patient’s medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending.

Contact:

James Nagle
V.P. Business Development
CutisPharma, Inc.
781-935-8141 x120